Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1152/ajprenal.00653.2013 http://scihub22266oqcxt.onion/10.1152/ajprenal.00653.2013 C4187047!4187047!25056353     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Am+J+Physiol+Renal+Physiol 2014 ; 307 (7): F777-82 Nephropedia Template TP {{tp|p=25056353|t=2014. Nanotechnology and adeno-associated virus-based decorin gene therapy ameliorates peritoneal fibrosis |pdf=|usr=}}{{25056353}} gab.com Text Nanotechnology and adeno-associated virus-based decorin gene therapy ameliorates peritoneal fibrosis JO: Am J Physiol Renal Physiol http://www.kidney.de/pget.php?&tw=1&pmid=25056353 #FOAvip Peritoneal dialysis (PD) is a life-sustaining therapy for end-stage renal disease (ESRD), used by 10?15% of the dialysis population worldwide. Peritoneal fibrosis (PF) is a known complication of long-term PD and frequently follows episodes of peritonitis, rendering the peritoneal membrane inadequate for dialysis. Transforming growth factor (TGF)-? is an inducer of fibrosis in several tissues and organs, and its overexpression has been correlated with PF. Animal models of peritonitis have shown an increase in expression of TGF-? in the peritoneal tissue. Decorin, a proteoglycan and component of the extracellular matrix, inactivates TGF-?, consequently reducing fibrosis in many tissues. Recently, gold nanoparticles (GNP) have been used for drug delivery in a variety of settings. In the present study, we tested the possibility that GNP-delivered decorin gene therapy ameliorates zymosan-mediated PF. We created a PF model using zymosan-induced peritonitis. Rats were treated with no decorin, GNP-decorin, or adeno-associated virus-decorin (AAV-decorin) and compared with controls. Tissue samples were then stained for Masson's trichrome, enface silver, and hematoxylin and eosin, and immunohistochemistry was carried out with antibodies to TGF-?1, ?-smooth muscle actin (?-SMA), and VEGF. Animals which were treated with GNP-decorin and AAV-decorin gene therapy had significant reductions in PF compared with untreated animals. Compared with untreated animals, the treated animals had better preserved peritoneal mesothelial cell size, a significant decrease in peritoneal thickness, and decreased ?-SMA. Quantitative PCR measurements showed a significant decrease in the peritoneal tissue levels of ?-SMA, TGF-?, and VEGF in treated vs. untreated animals. This study shows that both GNP-delivered and AAV-mediated decorin gene therapies significantly decrease PF in vivo in a rodent model. This approach has important clinical translational potential in providing a therapeutic strategy to prevent PF in PD patients. Twit Text FOAVip Nanotechnology and adeno-associated virus-based decorin gene therapy ameliorates peritoneal fibrosis ????Am J Physiol Renal Physiol http://www.kidney.de/pget.php?&tw=1&pmid=25056353 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=25056353 #FOAvip English Wikipedia <ref>{{Cite pmid|25056353}}</ref> Nanotechnology and adeno-associated virus-based decorin gene therapy ameliorates peritoneal fibrosis #MMPMID25056353 Chaudhary K; Moore H; Tandon A; Gupta S; Khanna R; Mohan RR Am J Physiol Renal Physiol 2014[Oct]; 307 (7): F777-82 PMID25056353show ga Peritoneal dialysis (PD) is a life-sustaining therapy for end-stage renal disease (ESRD), used by 10?15% of the dialysis population worldwide. Peritoneal fibrosis (PF) is a known complication of long-term PD and frequently follows episodes of peritonitis, rendering the peritoneal membrane inadequate for dialysis. Transforming growth factor (TGF)-? is an inducer of fibrosis in several tissues and organs, and its overexpression has been correlated with PF. Animal models of peritonitis have shown an increase in expression of TGF-? in the peritoneal tissue. Decorin, a proteoglycan and component of the extracellular matrix, inactivates TGF-?, consequently reducing fibrosis in many tissues. Recently, gold nanoparticles (GNP) have been used for drug delivery in a variety of settings. In the present study, we tested the possibility that GNP-delivered decorin gene therapy ameliorates zymosan-mediated PF. We created a PF model using zymosan-induced peritonitis. Rats were treated with no decorin, GNP-decorin, or adeno-associated virus-decorin (AAV-decorin) and compared with controls. Tissue samples were then stained for Masson's trichrome, enface silver, and hematoxylin and eosin, and immunohistochemistry was carried out with antibodies to TGF-?1, ?-smooth muscle actin (?-SMA), and VEGF. Animals which were treated with GNP-decorin and AAV-decorin gene therapy had significant reductions in PF compared with untreated animals. Compared with untreated animals, the treated animals had better preserved peritoneal mesothelial cell size, a significant decrease in peritoneal thickness, and decreased ?-SMA. Quantitative PCR measurements showed a significant decrease in the peritoneal tissue levels of ?-SMA, TGF-?, and VEGF in treated vs. untreated animals. This study shows that both GNP-delivered and AAV-mediated decorin gene therapies significantly decrease PF in vivo in a rodent model. This approach has important clinical translational potential in providing a therapeutic strategy to prevent PF in PD patients. äNanotechnology and adeno-associated virus-based decorin gene therapy a(epmc).pdf DeepDyve Pubget Overpricing